1. Ophthalmology 2022 Mar;129(3):322-333. doi: 10.1016/j.ophtha.2021.10.016. Epub 2021 Oct 22. Efficacy and Safety of 8 Atropine Concentrations for Myopia Control in Children: A Network Meta-Analysis Ahnul Ha 1, Seong Joon Kim 2, Sung Ryul Shim 3, Young Kook Kim 4, Jae Ho Jung 5 2. Efficacy Comparison of 16 Interventions for Myopia Control in Children: A Network Meta-analysis. Huang J, Wen D, Wang Q, McAlinden C, Flitcroft I, Chen H, Saw SM, Chen H, Bao F, Zhao Y, Hu L, Li X, Gao R, Lu W, Du Y, Jinag Z, Yu A, Lian H, Jiang Q, Yu Y, Qu J.Ophthalmology. 2016 Apr;123(4):697-708. doi: 10.1016/j.ophtha.2015.11.010. Epub 2016 Jan 27.PMID: 26826749 3. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, Tan D.Ophthalmology. 2012 Feb;119(2):347-54. doi: 10.1016/j.ophtha.2011.07.031. Epub 2011 Oct 2 4. Myopia progression after cessation of atropine in children: a systematic review and meta-analysis. Lee SH, Tsai PC, Chiu YC, Wang JH, Chiu CJ.Front Pharmacol. 2024 Jan 22;15:1343698. doi: 10.3389/fphar.2024.1343698. eCollection 2024. 5. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, Ko ST, Young AL, Tham CC, Chen LJ, Pang CP.Ophthalmology. 2019 Jan;126(1):113-124. doi: 10.1016/j.ophtha.2018.05.029. Epub 2018 Jul 6. 6. Biological Mechanisms of Atropine Control of Myopia. Upadhyay A, Beuerman RW.Eye Contact Lens. 2020 May;46(3):129-135. doi: 10.1097/ICL.0000000000000677. 7. Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis. Gong Q, Janowski M, Luo M, Wei H, Chen B, Yang G, Liu L.JAMA Ophthalmol. 2017 Jun 1;135(6):624-630. doi: 10.1001/jamaophthalmol.2017.1091. 8. Update in myopia and treatment strategy of atropine use in myopia control. Wu PC, Chuang MN, Choi J, Chen H, Wu G, Ohno-Matsui K, Jonas JB, Cheung CMG.Eye (Lond). 2019 Jan;33(1):3-13. doi: 10.1038/s41433-018-0139-7. Epub 2018 Jun 11.PMID: 29891900 Free PMC article. Review. It is believed that high myopia in adulthood can be traced back to school age onset myopia. ...Atropine is currently the most effective therapy for myopia control. ... 9. IMI Prevention of Myopia and Its Progression. Jonas JB, Ang M, Cho P, Guggenheim JA, He MG, Jong M, Logan NS, Liu M, Morgan I, Ohno-Matsui K, Pärssinen O, Resnikoff S, Sankaridurg P, Saw SM, Smith EL 3rd, Tan DTH, Walline JJ, Wildsoet CF, Wu PC, Zhu X, Wolffsohn JS.Invest Ophthalmol Vis Sci. 2021 Apr 28;62(5):6. doi: 10.1167/iovs.62.5.6.PMID: 33909032 Free PMC article. Review. 10. Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout: Phase 3 Report. Yam JC, Zhang XJ, Zhang Y, Wang YM, Tang SM, Li FF, Kam KW, Ko ST, Yip BHK, Young AL, Tham CC, Chen LJ, Pang CP.Ophthalmology. 2022 Mar;129(3):308-321. doi: 10.1016/j.ophtha.2021.10.002. Epub 2021 Oct 7.PMID: 34627809 Clinical Trial. 11, A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. Chamberlain P, Peixoto-de-Matos SC, Logan NS, Ngo C, Jones D, Young G.Optom Vis Sci. 2019 Aug;96(8):556-567. doi: 10.1097/OPX.0000000000001410.PMID: 31343513 Clinical Trial. 12. Slowing the Progression of Myopia in Children with the MiSight Contact Lens: A Narrative Review of the Evidence. Ruiz-Pomeda A, Villa-Collar C.Ophthalmol Ther. 2020 Dec;9(4):783-795. doi: 10.1007/s40123-020-00298-y. Epub 2020 Sep 11.PMID: 32915454 Free PMC article. Review. 13. Axial length targets for myopia control. Chamberlain P, Lazon de la Jara P, Arumugam B, Bullimore MA.Ophthalmic Physiol Opt. 2021 May;41(3):523-531. doi: 10.1111/opo.12812. Epub 2021 May 5.PMID: 33951213 Free PMC article. Clinical Trial. 14, Rebound Effect in the Misight Assessment Study Spain (Mass). Ruiz-Pomeda A, Prieto-Garrido FL, Hernández Verdejo JL, Villa-Collar C.Curr Eye Res. 2021 Aug;46(8):1223-1226. doi: 10.1080/02713683.2021.1878227. Epub 2021 Jan 24.PMID: 33460537 15. MiSight Assessment Study Spain (MASS). A 2-year randomized clinical trial. Ruiz-Pomeda A, Pérez-Sánchez B, Valls I, Prieto-Garrido FL, Gutiérrez-Ortega R, Villa-Collar C.Graefes Arch Clin Exp Ophthalmol. 2018 May;256(5):1011-1021. doi: 10.1007/s00417-018-3906-z. Epub 2018 Feb 3.PMID: 29396662 Clinical Trial. 16. Low-Concentration Atropine Monotherapy vs. Combined with MiSight 1 Day Contact Lenses for Myopia Management. Erdinest N, London N, Lavy I, Landau D, Ben Ephraim Noyman D, Levinger N, Morad Y.Vision (Basel). 2022 Dec 12;6(4):73. doi: 10.3390/vision6040073 17/Long-term Effect of Dual-focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. Chamberlain P, Bradley A, Arumugam B, Hammond D, McNally J, Logan NS, Jones D, Ngo C, Peixoto-de-Matos SC, Hunt C, Young G.Optom Vis Sci. 2022 Mar 1;99(3):204-212. doi: 10.1097/OPX.0000000000001873. 18. Effectiveness of myopia control interventions: A systematic review of 12 randomized control trials published between 2019 and 2021. Lanca C, Pang CP, Grzybowski A.Front Public Health. 2023 Mar 23;11:1125000. doi: 10.3389/fpubh.2023.1125000. eCollection 2023.PMID: 37033047 Free PMC article. Review. 19. Topical Review: Studies on Management of Myopia Progression from 2019 to 2021. Lanca C, Repka MX, Grzybowski A.Optom Vis Sci. 2023 Jan 1;100(1):23-30. doi: 10.1097/OPX.0000000000001947. Epub 2022 Oct 19.PMID: 36705712 Review. 20. Myopia Control With Orthokeratology: A Review. Hiraoka T.Eye Contact Lens. 2022 Mar 1;48(3):100-104. doi: 10.1097/ICL.0000000000000867.PMID: 34860723 Review. 21. The Safety of Orthokeratology--A Systematic Review. Liu YM, Xie P.Eye Contact Lens. 2016 Jan;42(1):35-42. doi: 10.1097/ICL.0000000000000219.PMID: 26704136 Free PMC article. Review.